Go Pro
OTCMKTS:EDTXF

Spectral Diagnostics Q3 2025 Earnings Report

Spectral Diagnostics logo
$1.00 +0.01 (+1.23%)
As of 12:35 PM Eastern

Spectral Diagnostics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Spectral Diagnostics Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
$0.54 million
Beat/Miss
Missed by -$56.00 thousand
YoY Revenue Growth
N/A

Spectral Diagnostics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Spectral Diagnostics' next earnings date is estimated for Friday, August 7, 2026, based on past reporting schedules.

Conference Call Resources

Spectral Diagnostics Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics (OTCMKTS:EDTXF) and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

View Spectral Diagnostics Profile